Because Tuberville sits on a defense, health-jurisdiction committee, we surface their disclosed transactions in companies within that sector. Source: U.S. House of Representatives Periodic Transaction Reports (PTRs).

Bristol-Myers Squibb(BMY)

Sale (full) · 2025-04-15 · $1,001 - $15,000

Conflict · Member, Senate Committee on Health, Education, Labor, and Pensions

PTR ↗

Eli Lilly and Company(LLY)

Sale (full) · Joint · 2025-04-15 · $15,001 - $50,000

Conflict · Member, Senate Committee on Health, Education, Labor, and Pensions

PTR ↗

Methodology note

Conflict-of-interest flagging is editorial. A disclosed trade is marked "Direct conflict" when the Member sits on a committee with significant jurisdiction over that trade's sector. Leadership roles (Chair, Ranking Member, Vice-Chair) receive more prominent treatment than ordinary committee membership. The label does not imply legal violation — Members are permitted to hold and trade individual securities under current law, including via managed accounts. Trades shown are disclosed PTR filings; the conflict assessment is our analytical lens on them.

Source: disclosures-clerk.house.gov, ingested via npm run ingest:house-ptrs

This Member doesn't yet have a deep editorial profile. What you see above — committee assignments, sponsored bills, and basic roster data — is all sourced from public datasets and rendered automatically. Deep editorial profiles (long bios, CPF earmark history, hand-curated notes on legislative priorities) are added incrementally for Members who are most active on appropriations or who appear in our SUS findings. If this Member should have a deeper profile, that's on our roadmap.

Roster data sourced from the public @unitedstates/congress-legislators dataset (CC0 license). Deep profile data hand-curated from Member websites, committee documents, House and Senate Appropriations CPF tables, and public bioguide records.